News

U.S. stock futures rise as Dow, S&P 500, Nasdaq edge higher; Tesla and Alphabet earnings loom, Trump’s tariff deadline fuels global trade fears
U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety ...
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets
Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug
Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.
Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy
Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...
Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse.
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...
Domino’s Pizza shares rise as U.S. same-store sales growth tops 3%
Domino’s Pizza, Inc. reported second-quarter earnings that missed analyst expectations despite solid sales growth, with shares rising 2.7% following the announcement.